Ligand Pharmaceuticals Company Profile (NASDAQ:LGND)

About Ligand Pharmaceuticals

Ligand Pharmaceuticals logoLigand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: LGND
  • CUSIP: 53220K50
Key Metrics:
  • Previous Close: $100.38
  • 50 Day Moving Average: $104.96
  • 200 Day Moving Average: $104.58
  • 52-Week Range: $20,898,000.00 - $87.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 23.29
  • P/E Growth: 0.84
  • Market Cap: $2.10B
  • Outstanding Shares: 20,898,000
  • Beta: 1.39
Profitability:
  • Net Margins: 8.51%
  • Return on Equity: 9.98%
  • Return on Assets: 5.56%
Debt:
  • Debt-to-Equity Ratio: 0.09%
  • Current Ratio: 0.62%
  • Quick Ratio: 0.60%
Additional Links:
Companies Related to Ligand Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ligand Pharmaceuticals (NASDAQ:LGND) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $136.86 (36.34% upside)

Analysts' Ratings History for Ligand Pharmaceuticals (NASDAQ:LGND)
Show:
DateFirmActionRatingPrice TargetDetails
2/27/2017Roth CapitalInitiated CoverageBuy$118.00View Rating Details
9/28/2016CJS SecuritiesLower Price TargetOutperform$130.00 -> $125.00View Rating Details
10/5/2016Craig HallumBoost Price Target$150.00 -> $160.00View Rating Details
10/5/2016HC WainwrightReiterated RatingBuy$146.00 -> $160.00View Rating Details
9/7/2016Deutsche Bank AGUpgradeSell -> Hold$110.00 -> $105.00View Rating Details
4/13/2016StephensInitiated CoverageOverweight$150.00View Rating Details
3/11/2016SidotiInitiated CoverageBuy$140.00View Rating Details
6/19/2015Cantor FitzgeraldBoost Price TargetHold$86.00 -> $93.00View Rating Details
3/3/2015CRT CapitalInitiated CoverageBuy$102.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Ligand Pharmaceuticals (NASDAQ:LGND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017        
2/23/2017Q416$1.19$0.74$40.34 million$38.20 millionViewN/AView Earnings Details
11/3/2016Q316$0.59$0.62$23.64 million$21.62 millionViewN/AView Earnings Details
8/4/2016Q216$0.40$0.50$18.12 million$19.50 millionViewN/AView Earnings Details
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details
2/10/2016Q415$0.65$0.66$24.71 million$21.20 millionViewListenView Earnings Details
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details
8/4/2015Q215$0.40$1.81$17.00 million$18.42 millionViewN/AView Earnings Details
5/11/2015Q115$0.27$0.33$13.50 million$14.60 millionViewListenView Earnings Details
2/9/2015Q414$0.60$0.60$23.88 million$23.00 millionViewN/AView Earnings Details
10/27/2014Q314$0.31$0.36$14.60 million$15.00 millionViewListenView Earnings Details
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ligand Pharmaceuticals (NASDAQ:LGND)
Current Year EPS Consensus Estimate: $4.73 EPS
Next Year EPS Consensus Estimate: $4.31 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.44$0.46$0.45
Q2 20161$0.54$0.54$0.54
Q3 20163$0.06$0.63$0.44
Q4 20163$0.69$1.16$0.98
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ligand Pharmaceuticals (NASDAQ:LGND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ligand Pharmaceuticals (NASDAQ:LGND)
Insider Ownership Percentage: 14.70%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/25/2016Jason AryehDirectorSell18,479$107.31$1,982,981.49View SEC Filing  
11/18/2016Jason AryehDirectorSell6,330$105.28$666,422.40View SEC Filing  
9/22/2016John L HigginsCEOSell3,000$117.34$352,020.00View SEC Filing  
9/7/2016John W KozarichDirectorSell1,000$115.00$115,000.00View SEC Filing  
9/1/2016John W KozarichDirectorSell1,666$105.40$175,596.40View SEC Filing  
8/1/2016John W KozarichDirectorSell1,000$137.57$137,570.00View SEC Filing  
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.00View SEC Filing  
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.00View SEC Filing  
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.00View SEC Filing  
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.00View SEC Filing  
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.00View SEC Filing  
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.00View SEC Filing  
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.00View SEC Filing  
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.22View SEC Filing  
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51View SEC Filing  
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.04View SEC Filing  
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.00View SEC Filing  
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.00View SEC Filing  
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.00View SEC Filing  
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.00View SEC Filing  
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.80View SEC Filing  
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.00View SEC Filing  
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.00View SEC Filing  
12/6/2013John SharpCFOSell6,000$56.08$336,480.00View SEC Filing  
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.00View SEC Filing  
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.42View SEC Filing  
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.29View SEC Filing  
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00View SEC Filing  
8/16/2013John SharpCFOSell7,500$42.75$320,625.00View SEC Filing  
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ligand Pharmaceuticals (NASDAQ:LGND)
DateHeadline
News IconLigand Pharmaceuticals Inc. (LGND) Issues Earnings Results, Misses Estimates By $0.45 EPS (NASDAQ:LGND)
www.graffiotech.com - February 25 at 5:57 PM
News IconThe Ligand Pharmaceuticals Inc. (LGND) Receives "Buy" Rating from the Roth Capital (NASDAQ:LGND)
prensariotiretail.com - February 25 at 5:57 PM
News IconMarket Scanner: Checking the Levels for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Providence Standard (NASDAQ:LGND)
providencestandard.com - February 25 at 8:23 AM
nasdaq.com logoOversold Conditions For Ligand Pharmaceuticals - Nasdaq.com - Nasdaq (NASDAQ:LGND)
www.nasdaq.com - February 25 at 8:23 AM
finance.yahoo.com logoEdited Transcript of LGND earnings conference call or presentation 23-Feb-17 9:30pm GMT (NASDAQ:LGND)
finance.yahoo.com - February 24 at 9:50 AM
investopedia.com logoThree Stocks Ripe For Bottom Fishing (NPTN, LGND) (NASDAQ:LGND)
www.investopedia.com - February 23 at 6:15 PM
nasdaq.com logoLigand Pharmaceuticals Inc Reports 31% Increase In Q4 Bottom Line (NASDAQ:LGND)
www.nasdaq.com - February 23 at 6:15 PM
biz.yahoo.com logoQ4 2016 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open (NASDAQ:LGND)
us.rd.yahoo.com - February 23 at 6:15 PM
us.rd.yahoo.com logoLigand Reports Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:LGND)
us.rd.yahoo.com - February 23 at 6:15 PM
biz.yahoo.com logoLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:LGND)
us.rd.yahoo.com - February 23 at 6:15 PM
sg.finance.yahoo.com logoLigand reports 4Q loss (NASDAQ:LGND)
sg.finance.yahoo.com - February 23 at 6:15 PM
News IconSell-side is Weighing in on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Earnings - Aiken Advocate (NASDAQ:LGND)
aikenadvocate.com - February 23 at 5:47 AM
nasdaq.com logoLigand (LGND) Q4 Earnings: Will the Stock Pull a Surprise? - Nasdaq (NASDAQ:LGND)
www.nasdaq.com - February 17 at 4:26 PM
capitalcube.com logoLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : February 17, 2017 (NASDAQ:LGND)
www.capitalcube.com - February 17 at 9:25 AM
us.rd.yahoo.com logoLigand (LGND) Q4 Earnings: Will the Stock Pull a Surprise? (NASDAQ:LGND)
us.rd.yahoo.com - February 16 at 4:59 PM
News IconMarket Review: Focusing on This Stock: Ligand Pharmaceuticals Incorporated (LGND) - Rives Journal (NASDAQ:LGND)
rivesjournal.com - February 15 at 9:22 PM
News IconWatching the Levels for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Midway Monitor (NASDAQ:LGND)
midwaymonitor.com - February 15 at 12:47 AM
News IconShares of Ligand Pharmaceuticals Incorporated (LGND) Sees Large Inflow of Net Money Flow - Highland Mirror (NASDAQ:LGND)
www.highlandmirror.com - February 15 at 12:47 AM
finance.yahoo.com logoDr. Christel Iffland Joins Ligand as Vice President, Antibody Technologies, Expands Team Focused on OmniAb Drug Discovery Platform (NASDAQ:LGND)
finance.yahoo.com - February 14 at 7:46 PM
finance.yahoo.com logoReminder: Ligand to Host Analyst Day on February 28th in New York City (NASDAQ:LGND)
finance.yahoo.com - February 13 at 7:21 PM
News IconStock Sheet: Reviewing the Levels for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Baldwin Journal (NASDAQ:LGND)
baldwinjournal.com - February 9 at 5:05 AM
News IconRk Capital Management LLC Has Boosted Ligand Pharmaceuticals INC (LGND) Holding as Market Value Declined (NASDAQ:LGND)
randolphguide.com - February 6 at 10:12 AM
News IconAs Ligand Pharmaceuticals Incorporated (LGND) Valuation Declined, Knott David M Has Lowered by $20.57 Million Its Position (NASDAQ:LGND)
randolphguide.com - February 3 at 6:57 PM
capitalcube.com logoLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : February 1, 2017 (NASDAQ:LGND)
www.capitalcube.com - February 1 at 7:04 PM
News IconF-Score Review on Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - The Tribune (NASDAQ:LGND)
lakecitytribune.com - January 30 at 10:13 AM
seekingalpha.com logoLigand Pharmaceuticals Incorporated (LGND) (NASDAQ:LGND)
seekingalpha.com - January 28 at 6:25 PM
News IconFCF Score Check on Shares of Ligand Pharmaceuticals ... - The Tribune (NASDAQ:LGND)
lakecitytribune.com - January 27 at 8:31 PM
biz.yahoo.com logoLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:LGND)
biz.yahoo.com - January 27 at 8:31 PM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Aiken Advocate (NASDAQ:LGND)
aikenadvocate.com - January 26 at 3:16 PM
News IconLigand Pharmaceuticals (LGND) Valuation Declined While Summit Creek Advisors LLC Has Raised Its Holding - The Randolph Guide (NASDAQ:LGND)
randolphguide.com - January 26 at 3:16 PM
News IconLigand Release: Pharma To Host Analyst Day On February 28th In New York City (NASDAQ:LGND)
www.biospace.com - January 25 at 7:40 PM
News IconLigand Release: Pharma To Report Fourth Quarter And Full Year 2016 Results On February 23rd (NASDAQ:LGND)
www.biospace.com - January 25 at 5:01 AM
finance.yahoo.com logoLigand to Host Analyst Day on February 28th in New York City (NASDAQ:LGND)
finance.yahoo.com - January 24 at 6:59 PM
4-traders.com logoLigand Pharmaceuticals : to Report Fourth Quarter and Full Year 2016 Results on February 23rd (NASDAQ:LGND)
www.4-traders.com - January 23 at 6:35 PM
finance.yahoo.com logoLigand to Report Fourth Quarter and Full Year 2016 Results on February 23rd (NASDAQ:LGND)
finance.yahoo.com - January 23 at 6:35 PM
4-traders.com logoLIGAND PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K) (NASDAQ:LGND)
www.4-traders.com - January 19 at 4:50 AM
capitalcube.com logoLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : January 18, 2017 (NASDAQ:LGND)
us.rd.yahoo.com - January 19 at 4:50 AM
biz.yahoo.com logoLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure (NASDAQ:LGND)
biz.yahoo.com - January 18 at 6:46 PM
feeds.reuters.com logoBRIEF-Ligand expects revenue related to Captisol material sales to be unchanged (NASDAQ:LGND)
feeds.reuters.com - January 18 at 6:19 PM
realistinvestor.com logoLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Mean Rating At $1.5 - RealistInvestor.com (NASDAQ:LGND)
www.realistinvestor.com - January 17 at 12:03 PM
News IconWill The Needle Move For Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:LGND)
wsbeacon.com - January 17 at 12:03 PM
finance.yahoo.com logoUPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Ligand Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 (NASDAQ:LGND)
finance.yahoo.com - January 13 at 7:32 PM
finance.yahoo.com logoEQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm (NASDAQ:LGND)
finance.yahoo.com - January 13 at 7:32 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm (NASDAQ:LGND)
finance.yahoo.com - January 12 at 6:46 PM
us.rd.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017 (NASDAQ:LGND)
us.rd.yahoo.com - January 11 at 11:57 PM
News IconCompany Stock Review for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Wall Street Beacon (NASDAQ:LGND)
wsbeacon.com - January 11 at 6:55 PM
News IconNext Weeks Broker Price Targets For Ligand Pharmaceuticals Incorporated (LGND) (NASDAQ:LGND)
diariocatolico.net - January 10 at 7:08 PM
finance.yahoo.com logoINVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm (NASDAQ:LGND)
finance.yahoo.com - January 10 at 7:08 PM
realistinvestor.com logoLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Mean Rating At $1.4 - RealistInvestor.com (NASDAQ:LGND)
www.realistinvestor.com - January 10 at 5:41 AM
News IconEquity Review: Looking Closer at Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Wall Street Beacon (NASDAQ:LGND)
wsbeacon.com - January 10 at 5:41 AM

Social

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Where is Ligand Pharmaceuticals' stock going? Where will Ligand Pharmaceuticals' stock price be in 2017?

6 brokerages have issued 12 month price objectives for Ligand Pharmaceuticals' shares. Their forecasts range from $105.00 to $160.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $136.86 in the next year.

When will Ligand Pharmaceuticals announce their earnings?

Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.

Who owns Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include William Blair Investment Management LLC (5.81%), Knott David M (4.78%), State Street Corp (4.06%), Cardinal Capital Management LLC CT (3.67%), FMR LLC (2.33%) and Russell Investments Group Ltd. (1.34%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, David M Knott, Jason Aryeh, John L Higgins, John W Kozarich, Matthew W Foehr, Melanie J Herman, Nishan M Desilva and Sunil Patel.

Who sold Ligand Pharmaceuticals stock? Who is selling Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Columbia Wanger Asset Management LLC, Guggenheim Capital LLC, State Street Corp, AQR Capital Management LLC, JW Asset Management LLC, Paradigm Asset Management Co. LLC and Turner Investments LLC. Company insiders that have sold Ligand Pharmaceuticals stock in the last year include Jason Aryeh, John L Higgins, John W Kozarich, Matthew W Foehr and Melanie J Herman.

Who bought Ligand Pharmaceuticals stock? Who is buying Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., William Blair Investment Management LLC, Cardinal Capital Management LLC CT, Janus Capital Management LLC, Osterweis Capital Management Inc., Gabelli Funds LLC, Employees Retirement System of Texas and RK Capital Management LLC.

How do I buy Ligand Pharmaceuticals stock?

Shares of Ligand Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ligand Pharmaceuticals stock cost?

One share of Ligand Pharmaceuticals stock can currently be purchased for approximately $100.38.

Ligand Pharmaceuticals (NASDAQ:LGND) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Earnings History Chart

Earnings by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Dividend History Chart

Dividend Payments by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Last Updated on 2/27/2017 by MarketBeat.com Staff